Physician profile
Theodore Kelbel
NPI 1326333444
$695,339.17
in general payments reported to CMS, 2019-2025
41 companies · $176K in 2025
The $176K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $38K · 2021: $66K · 2022: $94K · 2023: $106K · 2024: $183K · 2025: $176K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $361K · Consulting Fee: $59K · Travel and Lodging: $31K · Food and Beverage: $14K · Honoraria: $350 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $360,690.70 |
| Consulting Fee | $58,800.82 |
| Travel and Lodging | $30,673.65 |
| Food and Beverage | $13,832.84 |
| Honoraria | $350.00 |
| Education | $179.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $158,645.51 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $93,954.84 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $84,740.10 | 2020-2025 | Takhzyro, Cinryze, Hyqvia |
| Genzyme Corporation | $65,494.36 | 2019-2025 | |
| Genentech USA, INC. | $63,629.98 | 2020-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $50,018.37 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $44,395.30 | 2021-2025 | Ruconest, Joenja |
| Amgen INC. | $34,948.32 | 2021-2024 | Tezspire, Tavneos |
| Ionis Pharmaceuticals, INC. | $23,336.11 | 2025 | Dawnzera, Donidalorsen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,159.31 | 2020-2024 | Spiriva, Spiriva Respimat, Stiolto Respimat |
| Regeneron Pharmaceuticals, INC. | $16,385.57 | 2019-2025 | Dupixent |
| Csl Behring | $15,586.76 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Ars Pharmaceuticals Operations, INC. | $8,351.47 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $7,321.93 | 2021-2025 | Orladeyo |
| Biocryst Pharmaceuticals, INC. | $6,491.91 | 2025 | Orladeyo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $1,041.05 | 2022-2025 | Sajazir |
| Phadia US INC. | $1,018.40 | 2021-2024 | Immunocap |
| Aimmune Therapeutics, INC. | $581.37 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $386.28 | 2020-2025 | |
| Shire North American Group INC | $341.22 | 2019 | |
| Incyte Corporation | $299.32 | 2022-2025 | Opzelura |
| Abbvie INC. | $197.01 | 2022-2024 | |
| Lilly USA, LLC | $143.10 | 2024-2025 | Ebglyss |
| Grifols USA, LLC | $138.74 | 2019-2023 | Xembify |
| Optinose US, INC. | $112.67 | 2019-2023 | |
| Pfizer INC. | $87.70 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $86.31 | 2020-2021 | |
| Blueprint Medicines Corporation | $77.90 | 2023-2024 | Ayvakit |
| Kaleo, INC. | $52.40 | 2021-2023 | Auvi-Q |
| Alk-Abello, INC | $47.87 | 2022-2023 | Odactra, Ragwitek, Grastek |
| Covis Pharma Gmbh | $42.40 | 2021 | |
| Merck Sharp & Dohme LLC | $39.94 | 2021-2023 | |
| Genentech, INC. | $34.89 | 2025 | Xolair |
| E.R. Squibb & Sons, L.L.C. | $25.20 | 2025 | Orencia |
| Organon LLC | $23.71 | 2025 | Vtama |
| Kiniksa Pharmaceuticals, LTD. | $21.40 | 2023 | Arcalyst |
| Sobi, INC | $19.61 | 2024 | |
| Mylan Institutional INC. | $17.68 | 2023 | |
| Vapotherm INC | $15.91 | 2021 | |
| Galderma Laboratories, L.P. | $14.83 | 2025 | Nemluvio |
| Horizon Therapeutics Plc | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Kelbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.